Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
暂无分享,去创建一个
Alexander Fraser | Mirela Ionescu | Paul Emery | P. Emery | A. Poole | D. Veale | U. Fearon | A. Fraser | Douglas J Veale | Ursula Fearon | R Clark Billinghurst | Richard Reece | Thomas Barwick | A Robin Poole | M. Ionescu | R. Billinghurst | R. Reece | T. Barwick
[1] A. Poole,et al. Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. , 1992, The Journal of clinical investigation.
[2] Y. Yoshihara,et al. Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. , 1993, Osteoarthritis and cartilage.
[3] Andreas Radbruch,et al. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. , 1999, Rheumatology.
[4] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[5] Mauro Alini,et al. 9 – Cellular Biology of Cartilage Degradation , 1995 .
[6] Y. Okada,et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis , 2000, Annals of the rheumatic diseases.
[7] B. Bresnihan,et al. Collagenase, cathepsin B and cathepsin L gene expression in the synovial membrane of patients with early inflammatory arthritis. , 1999, Rheumatology.
[8] C. Rorabeck,et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. , 1994, The Journal of clinical investigation.
[9] N. Ishiguro,et al. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. , 1999, Arthritis and rheumatism.
[10] D. Taylor,et al. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. , 1994, Annals of the rheumatic diseases.
[11] T. Sawai,et al. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. , 1995, Annals of the rheumatic diseases.
[12] 廣畑 和志,et al. Cartilage in health and disease , 1985 .
[13] N. Fujimoto,et al. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[14] C. Rorabeck,et al. Damage to type II collagen in aging and osteoarthritis starts at the articular surface, originates around chondrocytes, and extends into the cartilage with progressive degeneration. , 1995, The Journal of clinical investigation.
[15] G. R. Dodge,et al. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. , 1989, The Journal of clinical investigation.
[16] A. Poole,et al. Early degradation of type IX and type II collagen with the onset of experimental inflammatory arthritis. , 2001, Arthritis and rheumatism.
[17] P. Dieppe,et al. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis. , 1994, The Journal of clinical investigation.
[18] H. Roos,et al. Procollagen II C-propeptide in joint fluid: changes in concentration with age, time after knee injury, and osteoarthritis. , 1996, The Journal of rheumatology.
[19] D. Veale,et al. Classification of clinical subsets in psoriatic arthritis. , 1994, British journal of rheumatology.
[20] A. Poole,et al. Relationships of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover and inflammation as revealed by analyses of synovial fluids from patients with rheumatoid arthritis. , 2001, Arthritis and rheumatism.
[21] P. Dieppe,et al. Evidence for altered synthesis of type II collagen in patients with osteoarthritis. , 1998, The Journal of clinical investigation.
[22] E. Thonar,et al. Serum keratan sulfate levels in osteoarthritis patients. , 1988, Arthritis and rheumatism.
[23] Michael J. Green,et al. The relationship between synovitis and bone changes in early untreated rheumatoid arthritis: a controlled magnetic resonance imaging study. , 1999, Arthritis and rheumatism.
[24] G. Verbruggen,et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity , 2000, Annals of the rheumatic diseases.
[25] A. So,et al. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. , 1999, Rheumatology.
[26] C. Rorabeck,et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. , 1997, The Journal of clinical investigation.
[27] G. Burmester,et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. , 1999, The Journal of rheumatology.
[28] J. Farrés,et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon γ is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies , 2000, Annals of the rheumatic diseases.
[29] Mainardi Cl. Biochemical mechanisms of articular destruction. , 1987 .
[30] Y. Yoshihara,et al. Significance of the levels of carboxy terminal type II procollagen peptide, chondroitin sulfate isomers, tissue inhibitor of metalloproteinases, and metalloproteinases in osteoarthritis joint fluid. , 1995, The Journal of rheumatology. Supplement.
[31] P. Emery,et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. , 1999, Arthritis and rheumatism.
[32] C. Richards,et al. Oncostatin M stimulates monocyte chemoattractant protein-1- and interleukin-1-induced matrix metalloproteinase-1 production by human synovial fibroblasts in vitro. , 1997, Arthritis and rheumatism.
[33] R. Moskowitz,et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. , 1986, Arthritis and rheumatism.
[34] B. Hazleman,et al. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. , 1993, Arthritis and rheumatism.
[35] E. Thonar,et al. Quantification of keratan sulfate in blood as a marker of cartilage catabolism. , 1985, The Journal of rheumatology.
[36] J. Ridgway,et al. Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology , 1999, Annals of the rheumatic diseases.
[37] E. Thonar,et al. Body fluid markers of cartilage changes in osteoarthritis. , 1993, Rheumatic diseases clinics of North America.
[38] Andreas Radbruch,et al. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. , 2000, Arthritis and rheumatism.
[39] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[40] P. Dieppe,et al. Biological markers in rheumatoid arthritis. , 1994, Seminars in arthritis and rheumatism.
[41] N. Fujimoto,et al. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.
[42] A. Poole,et al. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. , 1999, Arthritis and rheumatism.
[43] A. Simon,et al. Divergent T-cell cytokine patterns in inflammatory arthritis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[44] F. Epstein,et al. Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.
[45] A. Poole,et al. Inflammation and cartilage metabolism in rheumatoid arthritis. Studies of the blood markers hyaluronic acid, orosomucoid, and keratan sulfate. , 1990, Arthritis and rheumatism.
[46] S. Wahl,et al. Secretory Leukocyte Protease Inhibitor Suppresses the Inflammation and Joint Damage of Bacterial Cell Wall–Induced Arthritis , 1999, The Journal of experimental medicine.
[47] H. Holman,et al. Measurement of patient outcome in arthritis. , 1980, Arthritis and rheumatism.
[48] J. Esdaile,et al. Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group--a review of 45 cases. , 1995, The Journal of rheumatology.
[49] Andreas Radbruch,et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. , 1999, Arthritis and rheumatism.
[50] B. Månsson,et al. Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. , 1995, The Journal of clinical investigation.
[51] E. Thonar,et al. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. , 1993, Arthritis and rheumatism.
[52] B. Bresnihan,et al. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. , 2001, Arthritis and rheumatism.
[53] B. Bresnihan,et al. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. , 1993, Arthritis and rheumatism.